
Preclinical Identification to Clinical Validation of Plasma Metabolomic Signature of Novel Signal Transduction InhibitorsFriday, 12 September 2014 at 15:25 ![]() Unique changes in plasma metabolite profiles were identified in preclinical tumour models with systemic modulation of the PI3K and RAS-RAF-MEK pathway that were validated in human subjects with advanced solid tumours. |